EMA recommends first EU treatment for spinal muscular atrophy
The European Medicines Agency (EMA), which evaluates medicinal products for use in EU, has recommended nusinersen (Spinraza; Biogen) as a treatment for patients with spinal muscular atrophy (SMA).
There is currently no approved therapy in the EU for SMA, a rare and often fatal genetic disease …